In vivo activities of farnesyl pyrophosphate synthase inhibitors against Leishmania donovani and Toxoplasma gondii

Vanessa Yardley, Anis A. Khan, Michael B. Martin, Teri R. Slifer, Fausto G. Araujo, Silvia N.J. Moreno, Roberto Docampo, Simon L. Croft, Eric Oldfield

Research output: Contribution to journalArticlepeer-review

Abstract

The in vivo activities of three bisphosphonates were determined against Leishmania donovani and Toxoplasma gondii. Alendronate was essentially inactive against both parasites. Pamidronate was active against L. donovani by intravenous administration. Risedronate had a 50% effective dosage of five 2.6-mg/kg of body weight intraperitoneal doses against L. donovani-infected mice but was less effective against T. gondii-infected mice.

Original languageEnglish (US)
Pages (from-to)929-931
Number of pages3
JournalAntimicrobial Agents and Chemotherapy
Volume46
Issue number3
DOIs
StatePublished - 2002

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'In vivo activities of farnesyl pyrophosphate synthase inhibitors against Leishmania donovani and Toxoplasma gondii'. Together they form a unique fingerprint.

Cite this